It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Tumors are comprised of a multitude of cell types spanning different microenvironments. Mass spectrometry imaging (MSI) has the potential to identify metabolic patterns within the tumor ecosystem and surrounding tissues, but conventional workflows have not yet fully integrated the breadth of experimental techniques in metabolomics. Here, we combine MSI, stable isotope labeling, and a spatial variant of Isotopologue Spectral Analysis to map distributions of metabolite abundances, nutrient contributions, and metabolic turnover fluxes across the brains of mice harboring GL261 glioma, a widely used model for glioblastoma. When integrated with MSI, the combination of ion mobility, desorption electrospray ionization, and matrix assisted laser desorption ionization reveals alterations in multiple anabolic pathways. De novo fatty acid synthesis flux is increased by approximately 3-fold in glioma relative to surrounding healthy tissue. Fatty acid elongation flux is elevated even higher at 8-fold relative to surrounding healthy tissue and highlights the importance of elongase activity in glioma.
Isotopologue spectral analysis was originally designed to assess metabolic fluxes from bulk samples. Here, the authors adapted this approach to infer fluxes from discrete regions in tissue by using mass spectrometry imaging, showing increased fatty acid synthesis flux in brain tumors of mice.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Washington University in St. Louis, Department of Chemistry, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University in St. Louis, Center for Metabolomics and Isotope Tracing, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University in St. Louis, Department of Medicine, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)
2 Washington University in St. Louis, Department of Medicine, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University in St. Louis, Department of Neurology, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University in St. Louis, Siteman Cancer Center, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)
3 Washington University in St. Louis, Department of Chemistry, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University in St. Louis, Center for Metabolomics and Isotope Tracing, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University in St. Louis, Department of Medicine, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University in St. Louis, Siteman Cancer Center, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)